- About Us
- Contact Us
On April 25, 2021, CanSino Biologics Inc. (here referred to as ‘CanSinoBIO’) launched a ceremony for their Covid-19 vaccine phase III production base in Tianjin, where Jianshun Biosciences Co., Ltd. was awarded as the ‘Outstanding Fighting the epidemic Contribution Supplier’.
viral vector vaccine for COVID-19 produced in China(Convidecia, Ad5-nCoV) was co-developed
by CanSinoBIO and the Institute of Bioengineering of the Academy of Military
Medical Sciences, and is the only single-dose vaccine currently approved for
marketing in China. Jianshun Biosciences
worked collaboratively with CanSinoBIO during the initial stage of media and
process development, and have significantly shorten the product development to
Jianshun Biosciences is the industrial leader in the field of cell culture media development and manufacturing. It has various in-house cell culture technologies to enable clients’ virus vaccine production using cells such as HEK293, Vero, and MDCK in efficient and cost-effective manners.